Pancreatic Cell News 8.01 January 9, 2017 | |
| |
TOP STORYResearchers performed whole-genome bisulfite sequencing, which is a comprehensive and unbiased method to study DNA methylation throughout the genome on a single nucleotide resolution, in pancreatic islets from donors with type 2 diabetes and non-diabetic controls. [Diabetes] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISThe authors evaluated the mechanisms involved in interferon-α-induced HLA class I expression in human beta cells and determined whether this cytokine contributes to endoplasmic reticulum stress and apoptosis. [Diabetologia] Abstract Investigators used cultured human and human islet amyloid polypeptide (IAPP) expressing mouse islets to investigate: (1) the role of IL-1β in amyloid-induced Fas upregulation; (2) the effects of IL-1β-induced β-cell dysfunction on proIAPP processing and amyloid formation. [Diabetes Obes Metab] Abstract FoxO1 Inhibits Accelerated β-Cell Aging in Pancreas-Specific SMAD7 Mutant Mice Researchers showed that pancreatic depletion of SMAD7 resulted in age-dependent increases in β-cell dysfunction, with accelerated glucose intolerance, followed by overt diabetes. [J Biol Chem] Full Article PANCREATIC CANCERThe authors evaluated the expression of phospho-Akt in pancreatic ductal adenocarcinoma tissues and cells, and investigated molecular mechanisms influencing the therapeutic potential of Akt inhibition in combination with gemcitabine. [J Hematol Oncol] Full Article Scientists screened 1120 FDA-approved compounds, fifteen candidates were selected, and their interactions with NUPR1 were characterized by experimental and simulation techniques. [Sci Rep] Full Article Researchers used quantitative proteomics to profile the composition of the extracellular matrix of pancreatic islets in a mouse model of insulinoma characterized by a precisely timed angiogenic switch. [Sci Rep] Full Article Researchers previously isolated a human pancreatic tumor-initiating cell line, KMC07, from a patient with acquired resistance to gemcitabine chemotherapy. To improve the anticancer effects of gemcitabine, they investigated the molecular mechanism of KMC07 cells’ resistance to gemcitabine. [Pancreas] Abstract IL-33 Acts as a Foe to MIA PaCa-2 Pancreatic Cancer Scientists investigated whether IL-33 has any direct effect on pancreatic cancer. Clonogenic survival assay, immunohistochemistry, TUNEL staining, proliferation, caspase-3 activity kits and RT-PCR were used to evaluate the effects of IL-33 on cell survival, proliferation and apoptosis of a pancreatic cancer cell line, MIA PaCa-2. [Med Oncol] Abstract Investigators found that HO-3867, a novel analog of the natural product curcumin, showed good antitumor activity at the concentration of 2 μmol/l in PANC-1 and BXPC-3 cells. Importantly, it was also found that HO-3867 treatment significantly induced reactive oxygen species production in human pancreatic cancer cell lines, inducing PANC-1 and BXPC-3 cells. [Anticancer Drugs] Abstract | |
| |
REVIEWSEmploying Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer In this review, the authors discuss how recent efforts delineating rewired metabolic networks in pancreatic cancer have revealed new in-roads to develop detection and treatment strategies for this dreadful disease. [Cancer Cell] Abstract Vitamin D and Diabetes Mellitus: Causal or Casual Association? The authors discuss up to date evidence linking vitamin D with the development of diabetes. Moreover, the role of vitamin D supplementation in the prevention of both types of diabetes is analyzed together with its role in improving glycemic control in diabetic patients. [Rev Endocr Metab Disord] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
INDUSTRY NEWSIpsen to Acquire Oncology Assets from Merrimack Pharmaceuticals Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan. Ipsen will be responsible for advancing the ongoing ONIVYDE clinical development program, which includes a Phase II trial in first-line previously untreated metastatic pancreatic cancer, a Phase II/III trial in relapsed small-cell lung cancer, and a Phase I pilot trial in breast cancer. [Ipsen] Press Release Bristol-Myers Squibb Company announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squibb’s Immuno-Oncology agent Opdivo and Janssen’s CD38-directed cytolytic antibody Darzalex in Phase Ib/II clinical studies in multiple myeloma and solid tumors including non-small cell lung cancer, pancreatic cancer, colorectal cancer, triple negative breast cancer and head and neck cancer. [Bristol-Myers Squibb Company] Press Release Celyad Announces Registration of the First Patient in the Belgian THINK trial Celyad announced that the first patient of the Therapeutic Immunotherapy with NKR-2 (THINK) trial started cell processing in Belgium. THINK is a multinational open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). [Celyad] Press Release Halozyme Announces Phase II Study In Advanced Pancreas Cancer Meets Key Endpoints Halozyme Therapeutics, Inc. reported topline results from the combined analysis of Stages I and II and Stage II alone of its HALO 202 study, a Phase II randomized, multi-center clinical trial of lead investigational drug PEGPH20 in combination with ABRAXANE® (nab-paclitaxel) and gemcitabine in stage IV pancreas cancer patients. [Halozyme Therapeutics, Inc.] Press Release Minomic Announces Clinical Study Update for MILGa in Prostate, Bladder and Pancreatic Cancers Minomic International Ltd. announced that it has completed enrollment and dosing of the first three patients in its pioneering clinical trial of MILGa, a chimeric version of Minomic’s MIL-38 anti-Glypican 1 antibody conjugated to the radioactive isotope 67Gallium. The MILGa Cancer Imaging Trial is a first-in-human study to evaluate the safety and tumor targeting of MILGa in patients with advanced prostate, bladder and pancreatic cancer. [Minomic International Ltd (Business Wire, Inc.)] Press Release CalciMedica Initiates Phase I Clinical Studies for CRAC Channel Inhibitor CalciMedica, Inc. announced that it started Phase I safety studies in healthy volunteers of a novel calcium release-activated calcium (CRAC) channel inhibitor, CM4620, intended to treat acute pancreatitis. [CalciMedica, Inc.] Press Release Case Western Receives $2.5 Million Helmsley Grant for ‘Smart’ Insulin Development The Leona M. and Harry B. Helmsley Charitable Trust awarded a $2.5 million grant to the Case Western Reserve University School of Medicine to continue research on a new form of insulin for those living with type 1 diabetes. [Case Western Reserve University (American Association for the Advancement of Science)] Press Release Intarcia Therapeutics, Inc. and the California Institute for Biomedical Research (Calibr) announced a strategic research collaboration focused on the development of a novel peptide therapeutic leveraging Calibr’s Stapled-Peptide Platform Technology. Intarcia plans to develop and administer this novel therapy in combination with Exenatide, by leveraging its proprietary Medici Drug Delivery Systemâ„¢. [Intarcia Therapeutics, Inc.] Press Release Lexicon Pharmaceuticals, Inc. announced the commencement of dosing in a Phase I clinical trial of LX2761, an orally-delivered small molecule compound for the potential treatment of diabetes. LX2761 is an internally generated compound and is designed to inhibit SGLT1 locally in the gastrointestinal tract without any significant inhibition of SGLT2 in the kidney. [Lexicon Pharmaceuticals, Inc.] Press Release The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include data from the landmark EMPA-REG OUTCOME® trial. The data show that empagliflozin reduced the risk for cardiovascular death compared with placebo when added to standard of care type 2 diabetes and cardiovascular medicines in adults with type 2 diabetes and established cardiovascular disease. [Eli Lilly and Company] Press Release Allele to Develop iPSC-Derived Cell Therapies with Focus on Diabetes and Spinal Cord Injury Allele Biotechnology & Pharmaceuticals announced that it has officially entered into the development of induced pluripotent stem cell (iPSC)-derived cell therapies after the development plan received strong support by the Scientific Advisory Board and was approved by the Board of Directors in December of 2016. [Allele Biotechnology & Pharmaceuticals] Press Release | |
| |
POLICY NEWSThe U.S. House of Representatives took a crucial step forward towards improving the care and well-being of Americans suffering from diabetes and its consequences with their passage of the National Clinical Care Commission Act, a legislative priority advocated by the American Association of Clinical Endocrinologists and the diabetes community at-large. [American Association of Clinical Endocrinologists] Editorial Brexit Vote Drives UK Academics to Think About Leaving A survey of more than 1,000 UK-based university staff suggests that the country’s vote to leave the European Union could drive an academic exodus. [Nature News] Editorial US Scientists Fear New Restrictions on Fetal-Tissue Research House Republicans conclude that tissue from aborted fetuses is of limited value for research and seek to reduce funding. [Nature News] Editorial
| |
EVENTSNEW Gordon Research Conference: Cell Growth & Proliferation Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Research Fellow – Pancreatic Cancer (Fred Hutchinson Cancer Research Center) Senior Scientist – Pancreatic Cell Research (STEMCELL Technologies Inc.) Postdoctoral Position – Pancreatic Cancer (University of Liege) Scientist – Insulin Secretion (Helmholtz Association) Principle Scientist – Translational Development (Celgene Corporation) Postdoctoral Researcher – Cell Biology (Northwestern University) Postdoctoral Researcher – Diabetes Research (Karolinska Institutet) Assistant Professor – Molecular Therapeutics (Dartmouth College/Geisel School of Medicine) Vice President – Pancreatic Cancer Disease Lead (Celgene Corporation) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Pancreatic Cell News Volume 8.01 | Jan 10 2017